Business Segments · Provision
Business Segments — Provision
Pfizer Business Segments — Provision decreased by 92.4% to $47.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 92.4%, from $617.00M to $47.00M. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ1 2019
Last reportedQ1 2026
Rolls up toRestructuring Charges
How to read this metric
An increase may signal higher tax burdens or the recognition of new legal or operational risks.
Detailed definition
Refers to the estimated amount set aside for specific liabilities or tax obligations related to the biopharmaceutical se...
Peer comparison
Standard accounting practice for accruals, comparable across all large-cap pharmaceutical firms.
Metric ID:
pfe_segment_biopharma_provisionHistorical Data
12 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $152.50M | $152.50M | $152.50M | -$4.00M | $50.00M | $62.00M | $246.00M | -$28.00M | $4.00M | $1.00M | $617.00M | $47.00M |
| QoQ Change | — | +0.0% | +0.0% | -102.6% | >999% | +24.0% | +296.8% | -111.4% | +114.3% | -75.0% | >999% | -92.4% |
| YoY Change | — | — | — | — | -67.2% | -59.3% | +61.3% | -600.0% | -92.0% | -98.4% | — | -92.4% |
Range-$28.00M – $617.00M
CAGR-34.8%
Avg YoY Growth-135.4%
Median YoY Growth-92.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Pfizer's business segments — provision?
- Pfizer (PFE) reported business segments — provision of $47.00M in Q1 2026.
- How has Pfizer's business segments — provision changed year-over-year?
- Pfizer's business segments — provision decreased by 92.4% year-over-year, from $617.00M to $47.00M.
- What does business segments — provision mean?
- Funds reserved to cover specific anticipated liabilities or tax obligations for the biopharma segment.